Nov 16, 2021 / NTS GMT
Unidentified Participant
Hello, everybody, and welcome to this webcast with the reason of us introducing two new biosimilar candidates to our portfolio and initial development of these two products. My name is Martin. I'm the CEO of an Xbrane Biopharma. I have with me, Siavash, our COO and Head of our biosimilar program. So we want to spend some time now to discuss our new portfolio and do the presentation of maybe 15, 20 minutes, or so. And then we'll have a session of Q&A.
Okay. So yes, starting with the (technical difficulty) the Capital Markets Day, which will be held in May this year (technical difficulty) quite some time to talk about similar market and what we regard to (technical difficulty) in the market and above all (technical difficulty) strong growth, which is expected in the market in coming years. On the back of multiple biological drugs (technical difficulty) and their patent protection and that being opened up distribution centers.
So one of the fastest-growing segments actually in the pharmaceutical market, we believe. It's a very good opportunity for us to tap into this market
Xbrane Biopharma at Redeye life science day 2021 Transcript
Nov 16, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers